CARTESIAN THERAPEUTICS INC (RNAC) Forecast, Price Target & Analyst Ratings

NASDAQ:RNAC • US8162123025

Current stock price

6.26 USD
-0.13 (-2.03%)
At close:
6.26 USD
0 (0%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CARTESIAN THERAPEUTICS INC (RNAC).

Forecast Snapshot

Consensus Price Target

Price Target
$36.28
+ 479.60% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
May 6, 2026
Period
Q1 / 2026
EPS Estimate
-$0.90
Revenue Estimate
101.827K
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
82.67%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$36.28
Upside
+ 479.60%
From current price of $6.26 to mean target of $36.28, Based on 15 analyst forecasts
Low
$16.16
Median
$39.78
High
$46.20

Price Target Revisions

1 Month
0.00%
3 Months
0.81%

Price Target Summary

15 Wall Street analysts provided a forecast for the next 12 months for RNAC. The average price target is 36.28 USD. This implies a price increase of 479.6% is expected in the next year compared to the current price of 6.26.
The average price target has been revised upward by 0.81% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

RNAC Current Analyst RatingRNAC Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6

Analyst Ratings History

RNAC Historical Analyst RatingsRNAC Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 5 10

Analyst Ratings Consensus

ChartMill Buy Consensus
82.67%
RNAC was analyzed by 15 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about RNAC.
In the previous month the buy percentage consensus was at a similar level.
RNAC was analyzed by 15 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-03-10WedbushReiterate Outperform -> Outperform
2026-03-09Cantor FitzgeraldUpgrade Neutral -> Overweight
2026-03-09NeedhamReiterate Buy -> Buy
2026-01-09NeedhamMaintains Buy -> Buy
2025-11-19HC Wainwright & Co.Maintains Buy -> Buy
2025-11-14BTIGMaintains Buy -> Buy
2025-07-09WedbushInitiate Outperform
2025-05-08NeedhamMaintains Buy -> Buy
2025-04-09NeedhamReiterate Buy -> Buy
2025-04-09HC Wainwright & Co.Reiterate Buy -> Buy
2025-03-14HC Wainwright & Co.Maintains Buy -> Buy
2025-03-13NeedhamReiterate Buy -> Buy
2025-01-28HC Wainwright & Co.Reiterate Buy -> Buy
2025-01-27NeedhamReiterate Buy -> Buy
2025-01-13NeedhamReiterate Buy -> Buy
2024-12-19BTIGInitiate Buy
2024-12-04HC Wainwright & Co.Reiterate Buy -> Buy
2024-12-03NeedhamReiterate Buy -> Buy
2024-11-25NeedhamReiterate Buy -> Buy
2024-11-08NeedhamReiterate Buy -> Buy
2024-11-08HC Wainwright & Co.Maintains Buy -> Buy
2024-10-16NeedhamReiterate Buy -> Buy
2024-09-13HC Wainwright & Co.Reiterate Buy -> Buy
2024-09-04HC Wainwright & Co.Reiterate Buy -> Buy
2024-08-12HC Wainwright & Co.Maintains Buy -> Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
May 6, 2026
Period
Q1 / 2026
EPS Estimate
-$0.90
Revenue Estimate
101.827K
Revenue Q2Q
-90.74%
EPS Q2Q
-32.50%
Number of Analysts
9

Next Earnings Revisions

Revenue (1 Month)
-28.90%
Revenue (3 Months)
-28.90%
EPS (1 Month)
-3.52%
EPS (3 Months)
-3.52%

Next Earnings Summary

RNAC is expected to report earnings on 5/6/2026. The consensus EPS estimate for the next earnings is -0.9 USD and the consensus revenue estimate is 101.83K USD.
The next earnings revenue estimate has been revised downward by 28.9% in the past 3 months. Downward revisions are a negative sign and indicate that analysts are more pessimistic about the next earnings compared to 3 months ago.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
RNAC revenue by date.RNAC revenue by date.
26.004M
-76.53%		38.913M
49.64%		2.797M
-92.81%		407.49K
-85.43%		407.49K26.494M
6,401.75%		92.291M
248.35%		222.45M
141.03%		469.84M
111.21%		684.06M
45.59%		873.17M
27.65%
EBITDA
YoY % growth
RNAC ebitda by date.RNAC ebitda by date.
-84.873M
-636.32%		-35.167M
58.57%		-83.746M
-138.14%		N/A-169.32M-184.62M
-9.04%		-96.9M
47.51%		-34.68M
64.21%		35.7M
202.94%		N/AN/A
EBIT
YoY % growth
RNAC ebit by date.RNAC ebit by date.
-85.716M
-689.60%		-36.318M
57.63%		-86.705M
-138.74%		-104.951M
-21.04%		-119.4M
-13.77%		-138.169M
-15.72%		-121.617M
11.98%		-52.895M
56.51%		87.21M
264.87%		206.04M
136.26%		274.75M
33.35%
Operating Margin
RNAC operating margin by date.RNAC operating margin by date.
-329.63%-93.33%-3,099.93%-25,755.49%-29,301.25%-521.51%-131.78%-23.78%18.56%30.12%31.47%
EPS
YoY % growth
RNAC eps by date.RNAC eps by date.
-10.20
-221.43%		-11.68
-14.51%		-5.13
56.08%		-3.44
32.97%		-3.83
-11.30%		-2.73
28.58%		-2.81
-2.61%		-2.63
6.18%		2.60
198.84%		N/AN/A

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27
EPS
Q2Q % growth		-0.90
-32.50%		-0.85
-270.34%		-0.75
45.80%		-0.79
77.86%		-0.79
12.55%		-0.78
8.08%		-0.80
-6.71%		-0.81
-2.26%
Revenue
Q2Q % growth		101.827K
-90.74%		101.827K
-65.83%		101.827K
-77.47%		101.827K
-89.25%		152.745K
50.01%		152.745K
50.01%		152.745K
50.01%		152.745K
50.01%
EBITDA
Q2Q % growth		N/AN/AN/AN/AN/AN/AN/AN/A
EBIT
Q2Q % growth		-24.716M
-12.91%		-25.72M
-17.92%		-26.418M
-25.40%		-28.034M
-27.78%		-29.036M
-17.48%		-29.206M
-13.55%		-29.886M
-13.13%		-30.056M
-7.21%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

RNAC Yearly Revenue VS EstimatesRNAC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M
RNAC Yearly EPS VS EstimatesRNAC Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -20 -40 -60 -80 -100

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
13.63%
EPS Next 5 Year
8.26%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
136.38%
Revenue Next 5 Year
156.44%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
-27.10%
EBIT Next 5 Year
10.05%
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

CARTESIAN THERAPEUTICS INC / RNAC Forecast FAQ

What is the price target for RNAC stock?

15 analysts have analysed RNAC and the average price target is 36.28 USD. This implies a price increase of 479.6% is expected in the next year compared to the current price of 6.26.

Can you provide the upcoming earnings date for CARTESIAN THERAPEUTICS INC?

CARTESIAN THERAPEUTICS INC (RNAC) will report earnings on 2026-05-06.

Can you provide the consensus estimates for CARTESIAN THERAPEUTICS INC next earnings?

The consensus EPS estimate for the next earnings of CARTESIAN THERAPEUTICS INC (RNAC) is -0.9 USD and the consensus revenue estimate is 101.83K USD.

What is the number of analysts for RNAC stock?

The number of analysts covering CARTESIAN THERAPEUTICS INC (RNAC) is 15.